Sign In
Last checked at 
20 Apr 2021 07:00
20 April 2021
Crimson Tide agrees three year SaaS contract with
World Federation of Haemophilia
Crimson Tide ("Crimson Tide" or "the Company" (AIM:TIDE), the provider of mpro5 is pleased to announce that it has signed a three year agreement with the World Federation of Haemophilia (WFH). This follows the successful completion of the pilot phase announced by the Company on January 26, 2021.
The agreement will initially enable up to 100 clinicians globally to use mpro5 to scan pharmaceuticals, verifying their expiry and authenticity, and allowing the WFH to gain real-time insights into product usage. The mpro5 platform will be integrated into WFH's DPUMS system enabling real-time data captured from mpro5 to be available to all users around the world, replacing the ineffective existing paper-based data input..
mpro5 provides barcode scanning, data analysis, and cloud-based services via Microsoft Azure, renowned for its reliability, scalability and security. This enables real-time information, automated alerting, and integration capabilities with the existing systems of the WFH, driving a more efficient, transparent, and safer supply chain. mpro5 has been used in healthcare for many years in the verification and patient management for the National Coagulation Centre (NCC) in Ireland. It has also been used in verification of counterfeit drugs for the World Health Organisation in Africa and Asia.
The WFH is based in Montreal, Canada and its vision is that of Treatment for All and that one day, all people with a bleeding disorder will enjoy a more certain future filled with promise, no matter where they live. The mission of the WFH is to improve and sustain care for people with inherited bleeding disorders around the world. In order to achieve this, the organisation actively pursues long-term relationships with individuals and organizations who share the values inherent in their comprehensive development model.
Barrie Whipp, Executive Chairman of Crimson Tide, said: "We are delighted that we have been able to demonstrate the unique qualities of mpro5 to the WFH in such a short space of time. This supports our belief that there are significant opportunities to use our solutions throughout the wider healthcare sector and to help deliver improved patient outcomes. We look forward to working with the WFH and supporting them in their outstanding work."
For further information:
Crimson Tide plc
Barrie Whipp / Luke Jeffrey +441892 542 444
finnCap (Nominated Adviser and Broker)
Corporate Finance: Julian Blunt / James Thompson +44 20 7220 0500
Corporate Broking: Andrew Burdis +44 20 7220 0500
Alma PR (Financial PR)
Josh Royston +44 7780 901979
For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/
Follow the stocks
